All News
Filter News
Found 809,065 articles
-
Halberd Corporation's Proprietary Technology for Alzheimer’s Disease Enters Stage 4 of 7 Stage Process
6/21/2021
Halberd Corporation's proprietary technology enters stage 4 to address Alzheimer's Disease (and other potential diseases); eradicating the antibody-disease combination through radiofrequency waves or laser or other means.
-
GSK and Vir Biotechnology Announce Continuing Progress of the COMET Clinical Development Program for Sotrovimab
6/21/2021
GlaxoSmithKline plc and Vir Biotechnology, Inc. announced final, confirmatory results from the Phase 3 COMET-ICE trial demonstrating that sotrovimab, an investigational SARS-CoV-2 monoclonal antibody, significantly reduced the risk of hospitalization or death among high-risk adult outpatients with mild-to-moderate COVID-19.
-
Tonix Pharmaceuticals Announces Program to Develop TNX-102 SL for the Treatment of Long COVID Syndrome, also Known as Post-Acute Sequelae of COVID-19 (PASC)
6/21/2021
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, announced it plans to develop TNX-102 SL as a potential treatment for Long COVID Syndrome which is now known officially as Post-Acute Sequelae of COVID-19.
-
HighTide Therapeutics Announces the Presentation of Topline Results of Phase 2 Study of HTD1801 in PSC Patients at the International Liver Congress 2021
6/21/2021
HighTide Therapeutics Inc. (“HighTide”), a clinical-stage biopharmaceutical company, today announced the topline results of the study of HTD1801 in primary sclerosing cholangitis (PSC) will be presented at the International Liver Congress 2021, 23-26 June.
-
Agios Submits New Drug Application to FDA for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency
6/21/2021
Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism developing and delivering innovative treatments for genetically defined diseases, announced that it has submitted a New Drug Application for mitapivat to the U.S. Food and Drug Administration for the treatment of adults with pyruvate kinase deficiency.
-
Fulcrum Therapeutics Announces Multiple Presentations at the 28th Annual FSHD Society International Research Congress (IRC)
6/21/2021
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced multiple presentations at the 28th Annual FSHD Society International Research Congress.
-
XOMA Declares Quarterly Preferred Stock Dividends
6/21/2021
XOMA Corporation today announced its Board of Directors has authorized the following cash dividends to holders of XOMA’s Series A and Series B Cumulative Preferred Stock:
-
Duke-NUS and GenScript Announce Notice of Allowance for U.S. Patent Application for SARS-CoV-2 Surrogate Virus Neutralization Test
6/21/2021
GenScript Biotech Corporation announced today that the U.S. Patent and Trade Office has issued a notice of allowance for the patent application for a novel Surrogate Virus Neutralization Technology.
-
Enochian BioSciences Announces Acquisition of Exclusive License for Potential Pan-Coronavirus and Pan-Influenza Inhaled Treatment and Prevention Technology
6/21/2021
Enochian BioSciences, Inc. announced that the company has acquired an exclusive license for an innovative technology to potentially treat and prevent all variants of coronavirus, including the cause of COVID-19, as well as influenza.
-
Applied Therapeutics to Present on Diabetic Cardiomyopathy and Prevalence of Disease at the 81st Scientific Sessions of the 2021 Annual Meeting of the American Diabetes Association
6/21/2021
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced a Product Theater presentation at the upcoming 81st Scientific Sessions of the annual 2021 American Diabetes Association meeting taking place virtually June 25-29.
-
FDA Authorizes Simultaneous Stem Cell Trials for Parkinson’s
6/21/2021
Houston area non-profit research organization Hope Biosciences Stem Cell Research Foundation has received Food and Drug Administration authorization for a Phase II clinical trial to assess the efficacy and safety of multiple intravenous infusions of allogeneic adipose-derived mesenchymal stem cells in improving activities of daily living and quality of life in subjects with Parkinson’s Disease.
-
Algenex and FATRO announce positive CVMP opinion for CrisBio-based vaccine for Rabbit Viral Haemorrhagic Disease
6/21/2021
Algenex SL and FATRO S.p.A announce that The Committee for Medical Products for Veterinary Use of the European Medicines Agency has recommended FATRO’S CrisBio®-based vaccine for Rabbit Haemorrhagic Disease for marketing authorization in the European Union.
-
Rapid Micro Biosystems Appoints Sean Maynard as Asia Pacific Commercial General Manager
6/21/2021
Rapid Micro Biosystems, Inc., is pleased to announce the addition of veteran Asia Pacific (APAC) commercial leader Sean Maynard to support its vision of becoming the trusted standard in the global microbial quality control (MQC) marketplace.
-
Theravance Biopharma, Inc. Announces Top-Line Results From Phase 2 Study of Nezulcitinib In Patients Hospitalized With Acute Lung Injury Due to COVID-19
6/21/2021
Theravance Biopharma, Inc., a diversified biopharmaceutical company primarily focused on the discovery, development, and commercialization of organ-selective medicines, announced top-line results from its Phase 2 study of 3 mg once-daily nezulcitinib compared to placebo, each in combination with standard of care.
-
Study Results of Sintilimab in Combination with Bevacizumab Biosimilar IBI305 for the First-Line Treatment of Hepatocellular Carcinoma Published in The Lancet Oncology
6/21/2021
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, announced that data from the ORIENT-32 study have been published in The Lancet Oncology.
-
Poxel Announces Participation and Presentations at the EASL (European Association for the Study of the Liver) International Liver CongressTM 2021
6/21/2021
POXEL SA, a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis announced its participation at the European Association for the Study of the Liver International Liver CongressTM which will be held from June 23-26, 2021.
-
Prestige Biopharma’s First-in-Class Pancreatic Cancer Treatment, PBP1510, Receives Approval for Clinical Trial in France
6/21/2021
Prestige BioPharma Limited specializing in the development of antibody therapeutics, announced that French National Agency for the Safety of Medicines and Health Products has approved a Phase 1/2a clinical trial of its first-in-class anti-PAUF monoclonal antibody, PBP1510, for the treatment of pancreatic cancer.
-
How Do Developing Spinal Cords Choose "Heads" or "Tails"?
6/21/2021
The progression from a round ball of cells to an embryo with a head and a tail is one of the most critical steps in an organism's development.
-
NovaBiotics Announces Cysteamine Bitartrate (NM002) Included in REMAP-CAP Phase 3 Clinical Trial for Community Acquired Pneumonia
6/21/2021
NovaBiotics Ltd, a privately held clinical stage company developing novel immune based therapies for life-threatening and life-limiting-diseases, announces that the Company's proprietary intravenous cysteamine bitartrate therapy candidate is included in a global Phase 3 clinical trial being conducted and funded as part of REMAP-CAP.
-
Centene Dedicates New East Coast Headquarters In Charlotte
6/21/2021
Centene Corporation dedicated its new East Coast headquarters in Charlotte. The first phase of construction, which broke ground in August 2020 and is anticipated to be completed in 2022, will span nine floors and include 800,000 square feet of meeting and office space.